Sialyl-Lewis-X Glyco-antigen Is Enriched on Cells with Persistent HIV Transcription During Therapy
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA635886 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR11874815_1.fastq.gz | Fastqsanger.gz | |||
| SRR11874815_2.fastq.gz | Fastqsanger.gz | |||
| SRR11874816_1.fastq.gz | Fastqsanger.gz | |||
| SRR11874816_2.fastq.gz | Fastqsanger.gz | |||
| SRR11874817_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 18 |
Similar Datasets
Project description:A comprehensive understanding of the phenotype of persistent HIV-infected cells, both transcriptionally-active and/or -inactive, is imperative for developing a cure. The relevance of cell-surface glycosylation to HIV persistence has never been explored. We characterized the relationship between cell-surface glycomic signatures and persistent HIV transcription in vivo. We found that the cell-surface of CD4+ T cells actively transcribing HIV, despite suppressive therapy, harbors high levels of fucosylated carbohydrate ligands, including the cell extravasation mediator Sialyl-Lewis-X (SLeX), compared to HIV-infected transcriptionally-inactive cells. These high levels of SLeX are induced by HIV transcription in vitro and are maintained after therapy in vivo. Cells with high SLeX are enriched with markers associated with HIV susceptibility, signaling pathways that drive HIV transcription, and pathways involved in leukocyte extravasation. Together, we describe a novel glycomic signature of HIV-infected transcriptionally-active cells that not only differentiates them from their transcriptionally-inactive counterparts, but also can impact their trafficking abilities.
2020-08-24 | GSE151453 | GEO
Project description: Not available
| S-EPMC7432956 | biostudies-literature
Project description:Dysregulation of glyco-gene expression in cancer can lead to aberrant glycans and glycoconjugates, which in turn can promote tumorigenesis. Cervical cancer display augmentation of aberrant sialylated glycans and increase of glyco-genes, which encoded enzymes participate in the sialylation pathways. Besides sialiltranferases, other glyco-genes, analyzed individually are reported as altered in cervical cancer. Here we show a comprehensive analysis of glyco-gene expression in cervical cancer to obtain a wide scenery of global changes in glycosylation pathways. First, we compared glyco-gene expression between normal tissue and cervical cancer. Second, we analyzed the glycogene expression in subtypes of cc to obtain hallmarks of glyco-gene expression in each case. Our results indicate that in cervical cancer the GPI-anchored biosynthesis is increased in cc while the synthesis of chondroitin and dermatan sulfate are decreased. Moreover, data show that adenocarcinoma displayed a homogenous glyco-gene expression pattern, where chondroitin /dermatan sulfate and heparan sulfate glycogenes are decreased, while keratan sulfate genes are increased. Dysregulation of glyco-gene expression in cancer can lead to aberrant glycans and glycoconjugates, which in turn can promote tumorigenesis. Cervical cancer display augmentation of aberrant sialylated glycans and increase of glyco-genes, which encoded enzymes participate in the sialylation pathways. Besides sialiltranferases, other glyco-genes, analyzed individually are reported as altered in cervical cancer. Here we show a comprehensive analysis of glyco-gene expression in cervical cancer to obtain a wide scenery of global changes in glycosylation pathways. First, we compared glyco-gene expression between normal tissue and cervical cancer. Second, we analyzed the glycogene expression in subtypes of cc to obtain hallmarks of glyco-gene expression in each case. Our results indicate that in cervical cancer the GPI-anchored biosynthesis is increased in cc while the synthesis of chondroitin and dermatan sulfate are decreased. Moreover, data show that adenocarcinoma displayed a homogenous glyco-gene expression pattern, where chondroitin /dermatan sulfate and heparan sulfate glycogenes are decreased, while keratan sulfate genes are increased.
2020-10-24 | GSE159976 | GEO
Project description:Cytolytic activity by CD8+ cytotoxic T lymphocytes (CTL) is a powerful tactic in the elimination of intracellular pathogens and tumor cells. The destructive capacity of CTL is progressively dampened during chronic infection - yet the environmental cues and molecular pathways controlling immune “exhaustion” remain unclear. We find CTL immunity is regulated by the central transcriptional response to hypoxia, mediated by the von-Hippel-Lindau/Hypoxia-Inducible-Factor (VHL/HIF) pathway. Deletion of VHL, the primary negative regulator of HIF, leads to lethal CTL-mediated immunopathology during chronic infection, and VHL-deficient CTL display enhanced control of persistent viral infection and neoplastic growth. We find HIF and oxygen influence expression of pivotal CTL transcription, effector and costimulatory-inhibitory molecules, which is relevant to strategies to promote viral and tumor clearance. To understand the role of the VHL/HIF pathway in regulating T cell responses to acute and persistant antigen in vivo, a mixture of ~10^4 WT and Vhl KO virus-specific CD8+ T cells (P14s) was transferred iv into uninfected WT host mice. After infection with either LCMV-Armstrong (acute viral infection) or LCMV-clone13 (persistent viral infection) we double-FACS isolated the responding P14 donor cells from pooled spleens from two sets of host mice to obtain duplicates for microarray for the four conditions, resulting in eight samples (2 WT Arm, 2 VHL KO Arm; 2 WT cl13, 2 VHL KO cl13) at 6 to 7 days post-infection. All conditions were sorted on KRLG1lo P14 cells. Note this was a mixed P14 transfer, so WT and KO cells were responding to infection in the same WT host mice to aid in normalizing effects such as antigen load and cytokine environment.
2013-09-29 | E-GEOD-50158 | biostudies-arrayexpress
Project description:Sialyl Lewis X (sLexX or CD15s) is a tetra-saccharide N-acetylneuraminic acid, galactose, fucose and N-acetylglucosamine (NeuAcα2,3Galβ1,4(Fucα1,3)-GlcNAc). CD15s is present on various leukocytes usually as O-linked glycans bound to surface molecules such as PSGL-1, CD43 and CD44. On leukocytes, CD15s plays crucial role in extravasation through the interaction with E-selection expressed ion surface of the activated epithelial blood vessels. We find in approximately 10% of individuals basophils lack CD15s on their surface and these basophils fail to roll on E-selectin coated surfaces. In humans, six α(1,3)-fucosyltransferases (FT), α(1,3)-FTs: FT3/FT4/FT5/FT6/FT7/FT9) catalyses the transfer of fucose to the terminal lactosaminyl glycans giving rise to Lewis X (CD15) and/or sialyl Lewis X (CD15s). To identify which enzyme(s), we perform RNA-sequencing of CD15shigh(CD15s Pos) and CD15slow (CD15s Neg) basophils from 6 individuals.
2021-06-15 | GSE122281 | GEO
Project description:Rattus norvegicus Lewis Targeted Locus (Loci)
| PRJNA171876 | ENA
Project description:Major challenges of CAR-T cell therapy include poor antigen sensitivity and cell persistence. Here we report a solution to these issues by exploiting CAR phase separation. We found that incorporation of an engineered CD3e motif, EB6I, to the conventional 28Z or BBZ CAR induced self-phase separation through cation-π interactions. EB6I CAR can form a mature immunological synapse with CD2 corolla to transduce efficient antigen and costimulatory signaling, while its tonic signaling remains at low levels. Functionally, EB6I CAR-T cells exhibited improved signaling and cytoxicity against low-antigen tumor and persistent tumor killing function. In multiple primary and relapsed murine tumor models, EB6I CAR-T cells exerted better antitumor functions than conventional CAR-T cells against blood and solid cancers. This study thus unveils a new CAR engineering strategy to improve CAR-T cell immunity by leveraging molecular condensation and signaling integration.
2024-10-05 | GSE278512 | GEO
Project description:We observed the effects of TDAG8-overexpression in Lewis lung carcinoma (LLC) cells on the gene expression pattern.
2010-09-06 | GSE18244 | GEO